COVID-19 与多药治疗和免疫接种（2020-2024 年）。

COVID-19 in Relation to Polypharmacy and Immunization (2020-2024).

机构信息

Medicina de Família, CAP Anton de Borja Centre Universitari, c/ Marconi-Cantonada Edison s/n, Consorci Sanitari de Terrassa, 08191 Rubí, Spain.

Laboratory of Surgical Neuroanatomy, Human Anatomy and Embryology Unit, Faculty of Medicine, Universitat de Barcelona, c/Casanova 143, 08036 Barcelona, Spain.

出版信息

Viruses. 2024 Sep 27;16(10):1533. doi: 10.3390/v16101533.

BACKGROUND

Observational studies reported worse COVID-19 evolution in relation to polypharmacy and reductions in COVID-19 hospital admissions and death in patients receiving chronic antihistamine treatment. The current profile of hospitalized patients with regard to different variants was analyzed to identify specific targets for future prospective trials.

METHODS

COVID-19 admissions to the Hospital of Terrassa (11 March 2020-28 August 2024 (n = 1457), from the integral Consorci Sanitari de Terrassa population (n = 167,386 people) were studied. Age, gender, the number of chronic treatments (nT), and immunization status were analyzed.

RESULTS

After 5 May 2023, 291 patients (54% females) required COVID hospitalization. Of these, 39% received >8 nT (23% receiving 5-7 nT), 70.2% were >70 years, and 93.4% survived. In total, 12% of patients admitted after 5 May 2024 were not vaccinated, while 59% received ≥4 vaccines (43% within the last 12 months). In total, 49% of admitted patients presented no previous infection (while 3% presented infection during the last year). Delta or Omicron variants would have accounted for ≥80% of admissions > 60 years compared to the first pandemic wave if no vaccines existed.

CONCLUSIONS

Patients > 70 years who receive ≥5 nT, without prior COVID-19 infections, should be the priority for prevention, with updated vaccination and early treatments to reduce hospitalizations.

背景

观察性研究报告称，与多种药物治疗相关的 COVID-19 病情恶化，以及接受慢性抗组胺治疗的患者 COVID-19 住院和死亡人数减少。分析了目前住院患者与不同变异体的情况，以确定未来前瞻性试验的具体目标。

方法

研究了 2020 年 3 月 11 日至 2024 年 8 月 28 日期间，Terrassa 医院（11 名患者，来自完整的 Consorci Sanitari de Terrassa 人群（167386 人）因 COVID-19 住院的患者。分析了年龄、性别、慢性治疗次数（nT）和免疫接种状况。

结果

2023 年 5 月 5 日之后，291 名患者（54%为女性）需要 COVID 住院治疗。其中，39%接受了>8 nT（23%接受了 5-7 nT），70.2%的患者年龄>70 岁，93.4%的患者存活。共有 12%的患者在 2024 年 5 月 5 日之后住院未接种疫苗，而 59%的患者接种了≥4 剂疫苗（43%在过去 12 个月内接种）。共有 49%的住院患者无既往感染（而 3%的患者在过去一年中感染）。如果不存在疫苗，Delta 或 Omicron 变异体将占>60 岁患者入院人数的≥80%，而不是第一波大流行。